α-Ketobenzothiazole Serine Protease Inhibitors of Aberrant HGF/c-MET and MSP/RON Kinase Pathway Signaling in Cancer

Clinical and Biological Significance of Hepsin Overexpression in Breast Cancer

(2016) Peng Xing et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Structure-based discovery of small molecule hepsin and HGFA protease inhibitors: Evaluation of potency and selectivity derived from distinct binding pockets

(2015) Francisco M. Franco et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of O-(3-carbamimidoylphenyl)-l-serine amides as matriptase inhibitors using a fragment-linking approach

(2015) Rajeev Goswami et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Structure-guided discovery of 2-aryl/pyridin-2-yl-1H-indole derivatives as potent and selective hepsin inhibitors

(2015) Rajeev Goswami et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

c-Myc Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers

(2015) Aijun Shen et al.   CANCER RESEARCH

SPINT2 Deregulation in Prostate Carcinoma

(2015) Márcia Santos Pereira et al.   JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY

Erk2 but not Erk1 regulates crosstalk between Met and EGFR in squamous cell carcinoma cell lines

(2015) Simone Gusenbauer et al.   Molecular Cancer

Design and Synthesis of Nonpeptide Inhibitors of Hepatocyte Growth Factor Activation

(2015) Phanindra K. M. Venukadasula et al.   ACS Medicinal Chemistry Letters

Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression

(2015) Satoru Sugie et al.   Human Cell

Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets

(2015) Katherine Chang et al.   Oncotarget

Mechanisms of resistance to EGFR tyrosine kinase inhibitors

(2015) Lihua Huang et al.   Acta Pharmaceutica Sinica B

Analysis of Subpocket Selectivity and Identification of Potent Selective Inhibitors for Matriptase and Matriptase-2

(2014) Dominic Duchêne et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the oncogenic Met receptor by antibodies and gene therapy

(2014) E Vigna et al.   ONCOGENE

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors

(2014) Elizabeth Smyth et al.   OncoTargets and Therapy

Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer

(2014) Zhenfu Han et al.   ACS Medicinal Chemistry Letters

Mechanisms of Hepatocyte Growth Factor Activation in Cancer Tissues

(2014) Makiko Kawaguchi et al.   Cancers

Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress

(2013) J. Jean Cui   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors

(2013) Rajeev Goswami et al.   ACS Medicinal Chemistry Letters

Knockdown of RON receptor kinase delays but does not prevent tumor progression while enhancing HGF/MET signaling in pancreatic cancer cell lines

(2013) S Zhao et al.   Oncogenesis

Cancer chemotherapy: A critical analysis of its 60 years of history

(2012) Darío Galmarini et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

An allosteric anti-hepsin antibody derived from a constrained phage display library

(2012) R. Ganesan et al.   PROTEIN ENGINEERING DESIGN & SELECTION

New 3-amidinophenylalanine-derived inhibitors of matriptase

(2012) Maya Hammami et al.   MedChemComm

Design and Synthesis of Potent, Selective Inhibitors of Matriptase

(2012) Éloïc Colombo et al.   ACS Medicinal Chemistry Letters

Ron Kinase Transphosphorylation Sustains MET Oncogene Addiction

(2011) S. Benvenuti et al.   CANCER RESEARCH

Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils

(2011) Davide Torti et al.   EMBO Molecular Medicine

Strong expression association between matriptase and its substrate prostasin in breast cancer

(2011) Christopher Bergum et al.   JOURNAL OF CELLULAR PHYSIOLOGY

A Reverse Binding Motif That Contributes to Specific Protease Inhibition by Antibodies

(2011) Eric L. Schneider et al.   JOURNAL OF MOLECULAR BIOLOGY

Conversion from the “oncogene addiction” to “drug addiction” by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation

(2011) Kenichi Suda et al.   LUNG CANCER

Proteolytic Activation of Pro-Macrophage-Stimulating Protein by Hepsin

(2011) R. Ganesan et al.   MOLECULAR CANCER RESEARCH

Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy

(2010) Ming-Hai Wang et al.   ACTA PHARMACOLOGICA SINICA

Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA

(2009) Kate A. Owen et al.   BIOCHEMICAL JOURNAL

Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stimulating protein

(2009) Makiko Kawaguchi et al.   FEBS Journal

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

(2009) C.-F. Gao et al.   MOLECULAR CANCER THERAPEUTICS

Unraveling the Allosteric Mechanism of Serine Protease Inhibition by an Antibody

(2009) Rajkumar Ganesan et al.   STRUCTURE

A History of Cancer Chemotherapy

(2008) Vincent T. DeVita et al.   CANCER RESEARCH

The Prognostic Significance of RON and MET Receptor Coexpression in Patients with Colorectal Cancer

(2008) Chung-Ta Lee et al.   DISEASES OF THE COLON & RECTUM